DMK · Dmk Pharmaceuticals Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | $4.76M | $2.21M | $16.53M | $22.11M | $13.07M | - |
| Cost of Revenue | $6.19M | $6.87M | $14.89M | $15.48M | $7.42M | - |
| Gross Profit | ($1.43M) | ($4.66M) | $1.63M | $6.64M | $5.29M | $5.65M |
| R&D | $10.38M | $11.26M | $8.28M | $10.38M | $18.79M | $7.53M |
| SG&A | $13.25M | $16.14M | $30.58M | $25.29M | $25.95M | $22.82M |
| Total Operating Expenses | - | - | - | - | - | - |
| D&A | $1.48M | $1.44M | $3.61M | $2.94M | $3.10M | $3.06M |
| Operating Income | ($25.06M) | ($32.07M) | ($49.78M) | ($29.35M) | ($39.46M) | ($24.79M) |
| Interest Expense | - | $6.6K | $159.6K | $123.3K | $157.8K | $231.3K |
| Income Tax | $2.0K | $796 | $2.2K | $8.7K | ($369.3K) | ($339.4K) |
| Net Income | ($26.48M) | ($45.83M) | ($49.39M) | ($29.31M) | ($39.01M) | ($25.54M) |
| EPS - Basic | ($0.32) | - | - | - | - | - |
| EPS - Diluted | ($0.32) | - | - | - | - | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.08M | $23.22M | $6.86M | $8.81M | $17.32M | $4.08M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | $1.24M | $418.6K | $3.12M | $2.06M | $3.28M | $1.82M |
| Accounts Payable | $7.94M | $3.75M | $3.49M | $4.27M | $4.17M | $2.92M |
| Current Assets | $9.27M | $35.20M | $12.52M | $13.88M | $25.78M | $21.46M |
| Total Assets | $10.93M | $38.30M | $30.87M | $47.84M | $58.36M | $51.40M |
| Current Liabilities | $11.40M | $11.22M | $19.93M | $10.21M | $11.55M | $8.79M |
| Long-term Debt | - | - | $891.4K | - | - | - |
| Total Liabilities | $11.58M | $12.42M | $27.37M | $11.80M | $11.67M | $11.86M |
| Stockholders' Equity | ($808.1K) | $25.88M | $3.50M | $36.04M | $46.69M | $39.55M |
| Retained Earnings | ($304.56M) | ($278.09M) | ($229.91M) | ($182.31M) | ($153.00M) | ($114.00M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($25.90M) | ($37.79M) | ($20.90M) | ($19.89M) | ($32.66M) | ($21.16M) |
| Investing Cash Flow | $3.48M | $282.7K | ($946.2K) | ($2.87M) | ($3.54M) | $260.7K |
| Financing Cash Flow | $285.0K | $53.94M | $19.89M | $12.29M | $37.13M | $21.91M |
| CapEx | $680.4K | $1.22M | $696.2K | $2.87M | $3.54M | $2.06M |
| Free Cash Flow | ($26.58M) | ($39.01M) | ($21.60M) | ($22.75M) | ($36.19M) | ($23.22M) |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | -30.1% | -211.1% | 9.9% | 30.0% | 40.5% | - |
| Operating margin | -526.9% | -1452.0% | -301.2% | -132.7% | -301.9% | - |
| EBITDA margin | -495.7% | -1387.0% | -279.4% | -119.4% | -278.2% | - |
| Net margin | -556.7% | -2074.9% | -298.8% | -132.5% | -298.4% | - |
| Free cash flow margin | -558.9% | -1766.2% | -130.7% | -102.9% | -276.8% | - |
| FCF / Net income | 1.00 | 0.85 | 0.44 | 0.78 | 0.93 | 0.91 |
| R&D / Revenue | 218.2% | 509.9% | 50.1% | 46.9% | 143.8% | - |
| SG&A / Revenue | 278.5% | 730.9% | 185.0% | 114.4% | 198.5% | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -242.2% | -119.7% | -160.0% | -61.3% | -66.8% | -49.7% |
| Return on equity | 3276.7% | -177.1% | -1412.2% | -81.3% | -83.5% | -64.6% |
| Return on invested capital | - | - | -896.0% | - | - | - |
| Liquidity | ||||||
| Current ratio | 0.81 | 3.14 | 0.63 | 1.36 | 2.23 | 2.44 |
| Quick ratio | 0.70 | 3.10 | 0.47 | 1.16 | 1.95 | 2.23 |
| Cash ratio | 0.09 | 2.07 | 0.34 | 0.86 | 1.50 | 0.46 |
| Leverage | ||||||
| Debt / Equity | - | - | 0.25 | - | - | - |
| Debt / Assets | - | - | 0.03 | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | -4823.2x | -311.8x | -238.1x | -250.1x | -107.2x |
| Equity multiplier | -13.53 | 1.48 | 8.83 | 1.33 | 1.25 | 1.30 |
| Liabilities / Assets | 1.06 | 0.32 | 0.89 | 0.25 | 0.20 | 0.23 |
| Efficiency | ||||||
| Asset turnover | 0.44 | 0.06 | 0.54 | 0.46 | 0.22 | - |
| Inventory turnover | 4.99 | 16.42 | 4.78 | 7.51 | 2.26 | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | 73d | 22d | 76d | 49d | 161d | - |
| Days payable outstanding | 468d | 199d | 86d | 101d | 205d | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 115.3% | -86.6% | -25.3% | 69.2% | - | - |
| Revenue CAGR (3y) | -40.1% | -44.7% | - | 50.6% | - | - |
| Revenue CAGR (5y) | - | -19.4% | - | - | - | - |
| Gross profit growth (YoY) | 69.3% | - | -75.4% | 25.5% | -6.4% | 248.9% |
| Operating income growth (YoY) | 21.9% | 35.6% | -69.6% | 25.6% | -59.2% | 1.6% |
| Net income growth (YoY) | 42.2% | 7.2% | -68.5% | 24.9% | -52.7% | -31.4% |
| EPS growth (YoY) | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 31.9% | -80.6% | 5.1% | 37.1% | -55.8% | -9.1% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | - | 640.0% | -90.3% | -22.8% | 18.1% | 56.4% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2020-12-31.
Business segments
$16.53M totalCompounded Pharmaceuticals$13.75M · 83.2%
Drug Development And Commercialization$2.78M · 16.8%
Product / service
$30.28M totalCompounded Pharmaceuticals$13.75M · 45.4%
Sterile Product$9.16M · 30.3%
Non Sterile Product$4.59M · 15.1%
Manufactured Product Other$2.78M · 9.2%
Stability scores
Altman Z′
FY 2022 · bankruptcy risk
-30.46
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2022 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing DMK PHARMACEUTICALS Corp against the 5 most active filers in the same SIC group.